[Form 4] Wave Life Sciences Ltd. Insider Trading Activity
Wave Life Sciences Ltd. (WVE) Director Aik Na Tan reported equity awards on 08/11/2025 under the company鈥檚 2025 Non-Employee Director Compensation Policy. The filing shows a grant of 25,400 restricted share units (RSUs) that vest 50% on the earlier of the 2026 annual general meeting or August 11, 2026 and 50% on the earlier of the 2027 annual general meeting or August 11, 2027. The reporting person was also granted a share option for 152,400 ordinary shares with an exercise price of $8.105, vesting 12.5% quarterly beginning August 11, 2025 over two years and expiring on 08/11/2030. After these reported transactions the form lists 40,388 ordinary shares and 152,400 derivative securities beneficially owned by the reporting person.
Wave Life Sciences Ltd. (WVE): il direttore Aik Na Tan ha comunicato l'assegnazione di strumenti azionari il 11 agosto 2025 ai sensi della 2025 Non-Employee Director Compensation Policy della societ脿. La segnalazione riporta una concessione di 25.400 restricted share units (RSU), di cui il 50% matura alla prima tra l'assemblea annuale 2026 o il 11 agosto 2026 e il restante 50% alla prima tra l'assemblea annuale 2027 o il 11 agosto 2027. Al reporting 猫 stata inoltre concessa un'opzione su 152.400 azioni ordinarie con prezzo di esercizio di $8.105, che matura del 12,5% ogni trimestre a partire dall'11 agosto 2025 per due anni e scade il 11 agosto 2030. Dopo queste operazioni il modulo indica che la persona segnalante detiene beneficiariamente 40.388 azioni ordinarie e 152.400 strumenti derivati.
Wave Life Sciences Ltd. (WVE): el director Aik Na Tan notific贸 adjudicaciones de capital el 11 de agosto de 2025 en virtud de la 2025 Non-Employee Director Compensation Policy de la compa帽铆a. La presentaci贸n muestra la concesi贸n de 25.400 restricted share units (RSU) que se devengan en un 50% en la primera de la junta general anual 2026 o el 11 de agosto de 2026, y el 50% restante en la primera de la junta general anual 2027 o el 11 de agosto de 2027. Adem谩s se le concedi贸 una opci贸n sobre 152.400 acciones ordinarias con precio de ejercicio de $8.105, que se devenga un 12,5% trimestralmente a partir del 11 de agosto de 2025 durante dos a帽os y expira el 11 de agosto de 2030. Tras estas operaciones, el formulario registra que la persona notificante posee a t铆tulo beneficiario 40.388 acciones ordinarias y 152.400 valores derivados.
Wave Life Sciences Ltd. (WVE)鞚� 鞚挫偓 Aik Na Tan鞚� 須岇偓鞚� 2025 Non-Employee Director Compensation Policy鞐� 霐半澕 2025雲� 8鞗� 11鞚�鞐� 歆�攵� 氤挫儊 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐� 霐半ゴ氅� 25,400臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)臧� 攵�鞐悩鞐堨溂氅�, 攴胳 50%電� 2026雲� 鞐半 欤检＜齑濏殞 霕愲姅 2026雲� 8鞗� 11鞚� 欷� 牍犽ジ 鞁滌爯鞐�, 雮橂ǜ歆� 50%電� 2027雲� 鞐半 欤检＜齑濏殞 霕愲姅 2027雲� 8鞗� 11鞚� 欷� 牍犽ジ 鞁滌爯鞐� 臧侁皝 頇曥爼霅╇媹雼�. 氤搓碃鞛愳棎瓴岆姅 霕愴暅 頄夓偓臧�瓴╈澊 $8.105鞚� 152,400欤� 氤错喌欤检棎 雽�頃� 欤检嫕鞓奠厴鞚� 攵�鞐悩鞐堨溂氅�, 鞚� 鞓奠厴鞚� 2025雲� 8鞗� 11鞚茧秬韯� 攵勱赴氤勲 12.5%鞌� 2雲� 霃欖晥 臧�靻嶌爜鞙茧 氩犾姢韺呺悩瓿�, 2030雲� 8鞗� 11鞚�鞐� 毵岆霅╇媹雼�. 鞚� 瓯半灅霌� 鞚错泟 鞝滌稖靹滊電� 氤搓碃鞛愱皜 40,388欤� 氤错喌欤�鞕赌 152,400臧滌潣 韺岇儩歃濌秾鞚� 鞁れ 氤挫湢頃橁碃 鞛堨潓鞚� 旮办灛頃橁碃 鞛堨姷雼堧嫟.
Wave Life Sciences Ltd. (WVE) : l'administrateur Aik Na Tan a d茅clar茅 des attributions de titres le 11 ao没t 2025 en vertu de la 2025 Non-Employee Director Compensation Policy de la soci茅t茅. Le d茅p么t indique l'octroi de 25 400 restricted share units (RSU), dont 50 % sont acquises 脿 la premi猫re 茅ch茅ance entre l'assembl茅e g茅n茅rale 2026 et le 11 ao没t 2026, et les 50 % restants 脿 la premi猫re 茅ch茅ance entre l'assembl茅e g茅n茅rale 2027 et le 11 ao没t 2027. La personne d茅clar茅e s'est 茅galement vu accorder une option portant sur 152 400 actions ordinaires au prix d'exercice de $8.105, acqu茅rant 12,5 % chaque trimestre 脿 compter du 11 ao没t 2025 pendant deux ans et expirant le 11 ao没t 2030. Apr猫s ces op茅rations, le formulaire indique que la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 40 388 actions ordinaires et 152 400 instruments d茅riv茅s.
Wave Life Sciences Ltd. (WVE): Direktor Aik Na Tan meldete Aktienzuwendungen am 11. August 2025 im Rahmen der 2025 Non-Employee Director Compensation Policy des Unternehmens. Die Einreichung weist die Gew盲hrung von 25.400 Restricted Share Units (RSU) aus, von denen 50% bei der fr眉heren von der Hauptversammlung 2026 oder dem 11. August 2026 und die restlichen 50% bei der fr眉heren von der Hauptversammlung 2027 oder dem 11. August 2027 f盲llig werden. Dem Meldenden wurde au脽erdem eine Option auf 152.400 St眉ck Stammaktien mit einem Aus眉bungspreis von $8.105 gew盲hrt, die ab dem 11. August 2025 viertelj盲hrlich zu je 12,5% 眉ber zwei Jahre vestet und am 11. August 2030 verf盲llt. Nach diesen gemeldeten Transaktionen listet das Formular 40.388 Stammaktien und 152.400 derivative Wertpapiere als wirtschaftliches Eigentum der meldenden Person.
- Equity-based compensation aligns the director鈥檚 interests with long-term shareholders via RSUs and options
- Clear vesting schedules (50%/50% for RSUs; 12.5% quarterly for options) support retention and transparency
- Potential dilution of up to 177,800 shares if the 25,400 RSUs vest and 152,400 options are exercised
- RSUs granted at $0.00 increase outstanding share count without cash proceeds to the company
Insights
TL;DR: Routine director compensation disclosed: RSUs plus options create retention incentives without immediate cash transfer.
The Form 4 documents a standard non-employee director award: 25,400 RSUs and a 152,400-share option at an $8.105 exercise price. Vesting schedules are time-based and staggered, aligning the director鈥檚 interests with long-term shareholder value while delaying potential dilution until vesting/exercise. The expiration date of 08/11/2030 gives multi-year optionality. From a market-impact perspective, this filing is routine and informational for governance and share-capital monitoring.
TL;DR: Compensation follows disclosed policy; vesting structure supports retention but increases potential outstanding shares.
The awards were granted pursuant to the company鈥檚 2025 Non-Employee Director Compensation Policy, with explicit vesting terms: RSUs vest in two equal installments tied to AGMs or calendar dates, and options vest quarterly at 12.5% increments over two years. These features indicate a focus on retention and alignment. The filing clearly discloses quantities, exercise price, vesting cadence, and expiration, meeting standard disclosure expectations for insider transactions.
Wave Life Sciences Ltd. (WVE): il direttore Aik Na Tan ha comunicato l'assegnazione di strumenti azionari il 11 agosto 2025 ai sensi della 2025 Non-Employee Director Compensation Policy della societ脿. La segnalazione riporta una concessione di 25.400 restricted share units (RSU), di cui il 50% matura alla prima tra l'assemblea annuale 2026 o il 11 agosto 2026 e il restante 50% alla prima tra l'assemblea annuale 2027 o il 11 agosto 2027. Al reporting 猫 stata inoltre concessa un'opzione su 152.400 azioni ordinarie con prezzo di esercizio di $8.105, che matura del 12,5% ogni trimestre a partire dall'11 agosto 2025 per due anni e scade il 11 agosto 2030. Dopo queste operazioni il modulo indica che la persona segnalante detiene beneficiariamente 40.388 azioni ordinarie e 152.400 strumenti derivati.
Wave Life Sciences Ltd. (WVE): el director Aik Na Tan notific贸 adjudicaciones de capital el 11 de agosto de 2025 en virtud de la 2025 Non-Employee Director Compensation Policy de la compa帽铆a. La presentaci贸n muestra la concesi贸n de 25.400 restricted share units (RSU) que se devengan en un 50% en la primera de la junta general anual 2026 o el 11 de agosto de 2026, y el 50% restante en la primera de la junta general anual 2027 o el 11 de agosto de 2027. Adem谩s se le concedi贸 una opci贸n sobre 152.400 acciones ordinarias con precio de ejercicio de $8.105, que se devenga un 12,5% trimestralmente a partir del 11 de agosto de 2025 durante dos a帽os y expira el 11 de agosto de 2030. Tras estas operaciones, el formulario registra que la persona notificante posee a t铆tulo beneficiario 40.388 acciones ordinarias y 152.400 valores derivados.
Wave Life Sciences Ltd. (WVE)鞚� 鞚挫偓 Aik Na Tan鞚� 須岇偓鞚� 2025 Non-Employee Director Compensation Policy鞐� 霐半澕 2025雲� 8鞗� 11鞚�鞐� 歆�攵� 氤挫儊 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐� 霐半ゴ氅� 25,400臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)臧� 攵�鞐悩鞐堨溂氅�, 攴胳 50%電� 2026雲� 鞐半 欤检＜齑濏殞 霕愲姅 2026雲� 8鞗� 11鞚� 欷� 牍犽ジ 鞁滌爯鞐�, 雮橂ǜ歆� 50%電� 2027雲� 鞐半 欤检＜齑濏殞 霕愲姅 2027雲� 8鞗� 11鞚� 欷� 牍犽ジ 鞁滌爯鞐� 臧侁皝 頇曥爼霅╇媹雼�. 氤搓碃鞛愳棎瓴岆姅 霕愴暅 頄夓偓臧�瓴╈澊 $8.105鞚� 152,400欤� 氤错喌欤检棎 雽�頃� 欤检嫕鞓奠厴鞚� 攵�鞐悩鞐堨溂氅�, 鞚� 鞓奠厴鞚� 2025雲� 8鞗� 11鞚茧秬韯� 攵勱赴氤勲 12.5%鞌� 2雲� 霃欖晥 臧�靻嶌爜鞙茧 氩犾姢韺呺悩瓿�, 2030雲� 8鞗� 11鞚�鞐� 毵岆霅╇媹雼�. 鞚� 瓯半灅霌� 鞚错泟 鞝滌稖靹滊電� 氤搓碃鞛愱皜 40,388欤� 氤错喌欤�鞕赌 152,400臧滌潣 韺岇儩歃濌秾鞚� 鞁れ 氤挫湢頃橁碃 鞛堨潓鞚� 旮办灛頃橁碃 鞛堨姷雼堧嫟.
Wave Life Sciences Ltd. (WVE) : l'administrateur Aik Na Tan a d茅clar茅 des attributions de titres le 11 ao没t 2025 en vertu de la 2025 Non-Employee Director Compensation Policy de la soci茅t茅. Le d茅p么t indique l'octroi de 25 400 restricted share units (RSU), dont 50 % sont acquises 脿 la premi猫re 茅ch茅ance entre l'assembl茅e g茅n茅rale 2026 et le 11 ao没t 2026, et les 50 % restants 脿 la premi猫re 茅ch茅ance entre l'assembl茅e g茅n茅rale 2027 et le 11 ao没t 2027. La personne d茅clar茅e s'est 茅galement vu accorder une option portant sur 152 400 actions ordinaires au prix d'exercice de $8.105, acqu茅rant 12,5 % chaque trimestre 脿 compter du 11 ao没t 2025 pendant deux ans et expirant le 11 ao没t 2030. Apr猫s ces op茅rations, le formulaire indique que la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 40 388 actions ordinaires et 152 400 instruments d茅riv茅s.
Wave Life Sciences Ltd. (WVE): Direktor Aik Na Tan meldete Aktienzuwendungen am 11. August 2025 im Rahmen der 2025 Non-Employee Director Compensation Policy des Unternehmens. Die Einreichung weist die Gew盲hrung von 25.400 Restricted Share Units (RSU) aus, von denen 50% bei der fr眉heren von der Hauptversammlung 2026 oder dem 11. August 2026 und die restlichen 50% bei der fr眉heren von der Hauptversammlung 2027 oder dem 11. August 2027 f盲llig werden. Dem Meldenden wurde au脽erdem eine Option auf 152.400 St眉ck Stammaktien mit einem Aus眉bungspreis von $8.105 gew盲hrt, die ab dem 11. August 2025 viertelj盲hrlich zu je 12,5% 眉ber zwei Jahre vestet und am 11. August 2030 verf盲llt. Nach diesen gemeldeten Transaktionen listet das Formular 40.388 Stammaktien und 152.400 derivative Wertpapiere als wirtschaftliches Eigentum der meldenden Person.
FAQ
What did Wave Life (WVE) director Aik Na Tan receive on 08/11/2025?
What is the exercise price and expiration for the options reported by WVE?
How do the RSUs vest for Aik Na Tan at Wave Life (WVE)?
What is the vesting schedule for the options disclosed in the WVE Form 4?
How many shares does the reporting person beneficially own after the reported transactions?
